Patent ID: 11878987
Assignee: BEIJING INNOCARE PHARMA TECH CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC C

Claim 0:
1. A compound as shown in formula I, or an isomer, prodrug, solvate, stable isotopic derivative or pharmaceutically acceptable salt thereof:, wherein:
L1 is selected from —NR6C(O)—, —NR6CON(R7)—, —NR6S(O)m— and —NR6S(O)mN(R7)—, of which NR6 is connected with the nitrogen-containing heteroaryl substituted by R1, R2, R3;
L2 is selected from C1-C8 alkylene, C2-C8 alkenylene, C2-C8 alkynylene and C3-C8 cyclylene, wherein the alkylene, alkenylene, alkynylene and cyclylene can be optionally substituted by one or more G1;
L3 is selected from a single bond, —O— and —N(Rx);
R1, R2, and R3 are each independently selected from hydrogen, halogen, cyano, C1-C8 alkyl, C3-C8 cyclyl, 3-8 membered heterocyclyl, aryl, heteroaryl, formyl, —NR8R9, —C(O)R10, carboxyl, alkenyl, alkynyl, —OR10, —OC(O)NR8R9, —C(O)OR10, —C(O)NR8R9, —NR11C(O)R10, —NR11C(O)NR8R9, —S(O)mR10, —N11S(O)mR10, —SR10, —S(O)mNR8R9 and —NR11S(O)mNR8R9, wherein the alkyl, cyclyl, heterocyclyl, aryl or heteroaryl are optionally substituted by one or more substituents selected from halogen, cyano, C1-C8 alkyl, C3-C8 cyclyl, 3-8 membered heterocyclyl, —OR12, —NR13R14, —OC(O)NR13R14, —C(O)OR12, —C(O)R12, —C(O)NR13R14, —NR15C(O)R12, —NR15C(O)NR13R14, —S(O)mR12, —NR15S(O)mR12, —SR12, —S(O)mNR13R14 and —NR15S(O)mNR13R14;
R4 is selected from hydrogen, halogen, cyano, C1-C8 alkyl, C3-C8 cyclyl, 3-8 membered heterocyclyl, aryl, heteroaryl, formyl, —C(O)R10, carboxyl, alkenyl, alkynyl, —OR10, —NR8R9, —OC(O)NR8R9, —C(O)OR10, —C(O)NR8R9, —NR8C(O)R10, —NR10C(O)NR8R9, —S(O)mR10, —NR8S(O)mR10, —SR10, —S(O)mNR8R9, and —NR10S(O)mNR8R9;
R5 is selected from hydrogen, halogen, cyano, C1-C8 alkyl, C3-C8 cyclyl, 3-8 membered heterocyclyl, aryl, heteroaryl, formyl, —C(O)R10, carboxyl, alkenyl, alkynyl, —OR10, —NR8R9, —OC(O)NR8R9, —C(O)OR10, —C(O)NR8R9, —NR8C(O)R10, —NR10C(O)NR8R9, —S(O)mR10, —NR8S(O)mR10, —SR10, —S(O)mNR8R9 and —NR10S(O)mNR8R9;
R6, R7, and Rx are each independently selected from hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, heteroalkyl, C3-C8 cyclyl, 3-8 membered monocyclic heterocyclyl, monocyclic heteroaryl, monocyclic aryl, alkenyl and alkynyl;
G1 is selected from halogen, cyano, C1-C8 alkyl, C3-C8 cyclyl, 3-8 membered heterocyclyl, aryl, heteroaryl, formyl, —NR8R9, —C(O)R10, carboxyl, alkenyl, alkynyl, —OR10, —OC(O)NR8R9, —C(O)OR10, —C(O)NR8R9, —NR11C(O)R10, —NR11C(O)NR8R9, —S(O)mR10, —N11S(O)mR10, —S(O)mNR8R9 and —NR11S(O)mNR8R9; when two G1s are connected to the same carbon atom or two adjacent carbon atoms, the two G1s can form a 3-8 membered cyclyl together with the carbon atom(s) connected with them;
R8, R9, R10, R11, R12, R13, R14, R15 and R16 are each independently selected from the group consisting of hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, heteroalkyl, C3-C8 cyclyl, 3-8 membered monocyclic heterocyclyl, monocyclic heteroaryl, monocyclic aryl, alkenyl and alkynyl, wherein R8 and R9, and R13 and R14 may form a 3-7 membered heterocyclyl;
and m is 1 or 2;
wherein the following compounds (1) to (7) are excluded:,